![Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study - Yimer - 2019 - British Journal of Haematology - Wiley Online Library Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study - Yimer - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/41697ede-3b91-4aa2-80f0-1700afb9cc33/bjh15806-fig-0001-m.jpg)
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study - Yimer - 2019 - British Journal of Haematology - Wiley Online Library
![Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-13-00426/article_deploy/html/images/pharmaceuticals-13-00426-g002.png?1606531029)
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Additional Trials | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
![Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma | Future Oncology Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2021-1176/asset/images/medium/figure2.gif)
Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma | Future Oncology
![JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma](https://pub.mdpi-res.com/jcm/jcm-09-01195/article_deploy/html/images/jcm-09-01195-g001.png?1587896714)
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
![Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments](https://www.frontiersin.org/files/Articles/624661/fonc-10-624661-HTML/image_m/fonc-10-624661-g001.jpg)
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
![Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine](https://www.thelancet.com/cms/attachment/246a9b8c-b60a-4f1d-a6cd-17e042ae24c4/gr1_lrg.jpg)
Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine
![CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram](https://www.researchgate.net/publication/336032148/figure/fig4/AS:807059306078209@1569429341451/CASTOR-study-design-RRMM-relapsed-or-refractory-multiple-myeloma-DVd_Q640.jpg)
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
![Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5996585/bin/APJON-5-270-g005.jpg)
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. - Abstract - Europe PMC
![Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study | BMJ Open Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/8/3/e021333/F1.large.jpg)